Primary Ovarian Mucinous Carcinoma: A Diagnosis Defined as Much by Exclusion as by Recognition

What It Is and Where It Sits in Current Classification

Mucinous carcinoma of the ovary is a recognized subtype of ovarian epithelial malignancy in the 5th edition of the WHO Classification of Female Genital Tumours [1]. It is characterized by neoplastic epithelium resembling that of the gastrointestinal tract — so-called gastrointestinal (GI)-type mucinous epithelium — arranged in glands and cysts and demonstrating invasive growth.

Two facts should anchor any discussion of this entity. First, primary ovarian mucinous carcinoma is genuinely rare. Many tumors that appear to be mucinous carcinomas of the ovary are, on careful workup, metastases to the ovary from other organs. Second, because of that reality, the diagnosis is defined as much by what it is not — a metastasis — as by its own intrinsic features. This dual character shapes the entire diagnostic approach and is the reason a pathologist must proceed methodically rather than accept a mucinous ovarian mass as primary at face value.

Mucinous neoplasms of the ovary span a biological continuum, from benign cystadenoma through borderline tumors to invasive carcinoma. Mucinous carcinoma occupies the malignant end of that spectrum, distinguished by the presence of stromal invasion.

How a Pathologist Recognizes It: Morphology → IHC → Molecular

The diagnostic sequence matters, and it proceeds in a deliberate order.

Morphology comes first. The tumor is composed of GI-type mucinous epithelium — tall columnar cells with apical mucin, sometimes with goblet-cell differentiation, forming glands and cystic spaces. The critical morphologic determination is the pattern of invasion, which the WHO framework describes in two forms [1]:

• Expansile (confluent) invasion, in which glands become so crowded and back-to-back that intervening stroma is effaced, producing a labyrinthine or confluent glandular proliferation without an obvious desmoplastic response.
• Infiltrative invasion, in which malignant glands, cell clusters, or single cells frankly infiltrate the stroma, often eliciting a desmoplastic reaction.

Recognizing invasion — and distinguishing it from the crowded but non-invasive architecture of a borderline tumor — is the first intellectual task. But morphology alone cannot settle the central question of primary versus metastatic origin, because a metastatic GI adenocarcinoma may closely mimic a primary ovarian mucinous tumor.

Immunohistochemistry is the second step, deployed specifically to address origin. The immunophenotype associated with primary ovarian mucinous carcinoma includes [1]:

• CK7 positive, with CK20 variable — a pattern that leans toward, but does not by itself prove, an ovarian (or upper-GI/pancreaticobiliary) origin.
• PAX8 often negative — notable because PAX8 is a Müllerian marker positive in many other ovarian epithelial tumors; its frequent absence here underscores the GI-type differentiation of this tumor.
• SATB2 negative, which helps exclude a lower gastrointestinal (colorectal/appendiceal) metastasis.
• WT1 negative, helping separate it from serous tumors, which are typically WT1 positive.

The clinical note reinforces the practical panel: when a lower-GI or appendiceal metastasis is on the table, SATB2, CK20, and CDX2 are the workhorse markers, and a diffusely SATB2-positive, CK20-predominant profile should raise strong suspicion for a colorectal or appendiceal primary rather than an ovarian one [1]. The evidence supports using immunohistochemistry as a directional tool that integrates with — but does not replace — morphology and clinical/radiologic correlation.

Molecular findings are the third layer. Primary ovarian mucinous carcinomas are associated with KRAS mutations, and a subset show HER2 (ERBB2) amplification [1]. These features are informative both biologically and, in the case of HER2, potentially for therapy-class eligibility (discussed below). Molecular testing does not stand alone as a proof of primary origin, but it contributes to a coherent picture when integrated with morphology and IHC.

Grading and Classification

Grading of ovarian mucinous carcinoma is performed by architecture and cytologic atypia [1]. In practical terms, the assessment weighs the degree of glandular complexity and architectural disorder together with nuclear atypia and mitotic activity. This architecture/atypia-based approach is distinct from the binary low-grade/high-grade paradigm used for serous carcinomas, and it reflects the different biology of the mucinous category. The pattern of invasion — expansile versus infiltrative — is itself part of the morphologic characterization and is documented as part of the diagnosis [1].

Why the Distinction Matters Clinically

The overriding clinical message is that excluding a metastasis is the critical task [1]. A GI-tract, appendiceal, or pancreaticobiliary adenocarcinoma metastatic to the ovary can masquerade as a primary ovarian mucinous carcinoma, and the two carry entirely different implications for staging, source-tumor evaluation, and management. Misclassifying a metastasis as an ovarian primary — or vice versa — sends the patient down the wrong diagnostic and management pathway. This is why the SATB2/CK20/CDX2 panel and correlation with clinical and radiologic findings are not optional refinements but essential components of the workup.

Certain morphologic and gross clues classically raise suspicion for metastasis (for example, bilaterality and small size favor metastatic disease in many settings), but immunohistochemistry provides the more objective discriminating evidence in routine practice [1].

The HER2 finding carries therapeutic relevance [1]. Because a subset of these tumors demonstrate HER2 amplification, HER2 testing is meaningful in the diagnostic evaluation — it identifies patients whose tumors fall into a category for which HER2-directed therapy classes may become relevant. This is a statement about drug-class eligibility as informed by a biomarker, not a recommendation of any specific treatment for any specific patient; management decisions belong to the treating clinical team.

A note on epistemic humility: the biology of ovarian mucinous carcinoma, including the frequency and prognostic weight of HER2 amplification and KRAS mutation, remains an area of ongoing study, and pathologists should interpret molecular results within the context of the full clinicopathologic picture rather than in isolation.

Summary

Primary ovarian mucinous carcinoma is a rare, recognized WHO5 subtype defined by GI-type mucinous epithelium and either expansile or infiltrative invasion [1]. Its diagnosis follows a disciplined sequence — morphology, then a targeted immunohistochemical panel (CK7/CK20, PAX8, SATB2, WT1) to interrogate origin, then molecular characterization (KRAS, HER2) — with the exclusion of a GI or pancreaticobiliary metastasis as the central, non-negotiable task [1].

References

1. WHO Classification of Tumours Editorial Board. Female Genital Tumours, 5th ed. IARC, Lyon; 2020. ISBN 978-92-832-4504-9.